Supplemental Table S3 .
NSCLCs were treated long-term with 1 M imetelstat and drug response phenotypes to a variety of chemotherapy and targeted therapy agents were determined using a 96-well MTS cell viability assay. Drugs were tested at 8 different drug concentrations each in octuplicate and assays were repeated three times. IC50s are displayedin the tablebelow. Imetelstat treatment occasionally increases the response to cytotoxic chemotherapy, but this is highly heterogeneous between tumors.
Supplemental Figure S4. Imetelstat Therapy in vivo Response is Dependent on
Initial Telomere Length and Therapy Duration. Paclitaxel/carboplatin combination was given in a 2:3 wt/wt ratio. Each drug was given at 8 drug concentrations per assay. Plates were incubated for four days and relative cell number was determined by incubating for 1 to 3 hours at 37°C in the presence of MTS (Promega, Madison, WI), final concentration 333 g/ml. Absorbance readings of the plate were obtained at 490 nm using a Spectra Max 190 (Molecular Devices). Each plate contained eight replicates per concentration and was repeated at least 4 times. Drug sensitivity curves and IC50s were calculated using in-house software, DIVISA.
Supplemental Methods

5-day Cell Viability
Serial Cloning
1000 H1648 cells were plated in a 10cm dish in the presence of 3 M imetelstat. 8 mm cloning cylinders lined with silicone grease were placed over surviving clones. 10 L trypin were added to the center of the ring and 50 L of RPMI +5% FBS media was used to harvest the cells and transfer to a new dish. These cells were allowed to proliferate and then used in the standard colony formation already described in the materials and methods. The colony formation assay was repeated a minimum of two times with each replicate done in triplicate. Subclones of these clones were then performed using this same protocol.
